CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Clin Transl Radiat Oncol
; 25: 61-66, 2020 Nov.
Article
in En
| MEDLINE
| ID: mdl-33072895
ATM, Ataxia telangiectasia mutated; ATR, Ataxia telangiectasia and Rad3 related; CRT, Chemoradiotherapy; CT, Computed tomography; CTCAE, Common terminology criteria for adverse events; CTRad, Clinical and Translational Radiotherapy Research Working Group; Continual reassessment method; DDRi, DNA damage response inhibitor; DLT, Dose limiting toxicity; DNA damage repair inhibitor; DNA, Deoxyribonucleic acid; DNA-PK, DNA-dependent protein kinase; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ICRU, International Commission on Radiation Units and Measurements; IMPs, Investigational medicinal products; LA, Locally advanced; MRC, Medical Research Council; NCRI, National Cancer Research Institute; NSCLC, Non-small cell lung cancer; Non-small cell lung cancer; PARP, Poly (ADP-ribose) polymerase; PET, Positron emission tomography; PFS, Progression free survival; PROMs, Patient-reported outcome measures; Platform trial; RECIST, Response evaluation criteria in solid tumours; RP2D, Recommended phase II dose; RT, Radiotherapy; SACT, Systemic anti-cancer therapy; SRC, Safety review committee; Sequential chemoradiotherapy; TNM, Tumour node metastasis; TiTE-CRM, Time to event continual reassessment method; cfDNA, Cell-free DNA
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Aspects:
Patient_preference
Language:
En
Journal:
Clin Transl Radiat Oncol
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: